Human striatal progenitor cells that contain inducible safeguards and overexpress BDNF rescue Huntington’s disease phenotypes in R6/2 mice

Danielle A. Simmons,Sridhar Selvaraj,Tingshuo Chen,Gloria Cao,Talita Sauto Camelo,Tyne L.M. McHugh,Selena Gonzalez,Renata Martin,Juste Simanauskaite,Nobuko Uchida,Matthew Porteus,Frank M. Longo
DOI: https://doi.org/10.1101/2024.05.01.592095
2024-05-01
Abstract:Huntington’s disease (HD) is an autosomal-dominant neurodegenerative disorder characterized by striatal atrophy. Reduced trophic support due to decreased striatal levels of neurotrophins (NTs), mainly brain-derived neurotrophic factor (BDNF), contributes importantly to HD pathogenesis; restoring NTs has significant therapeutic potential. Human pluripotent stem cells (hPSC) offer a scalable platform for NT delivery but has potential safety risks including teratoma formation. We engineered hPSCs to constitutively produce BDNF and contain inducible safeguards to eliminate these cells if safety concerns arise. This study examined the efficacy of intrastriatally transplanted striatal progenitor cells (STRpcs) derived from these hPSCs against HD phenotypes in R6/2 mice. Engrafted STRpcs overexpressing BDNF alleviated motor and cognitive deficits and reduced mutant huntingtin aggregates. Activating the inducible safety switch with rapamycin safely eliminated the engrafted cells. These results demonstrate that BDNF delivery via a novel hPSC-based platform incorporating safety switches could be a safe and effective HD therapeutic.
Neuroscience
What problem does this paper attempt to address?
This paper attempts to solve the problems of striatal atrophy and related motor and cognitive dysfunctions in Huntington's Disease (HD) caused by the reduction of neurotrophic factors, especially brain - derived neurotrophic factor (BDNF). Specifically, the researchers developed a treatment platform based on human pluripotent stem cells (hPSCs). These cells were engineered to continuously produce BDNF and contain inducible safety mechanisms so that these cells can be eliminated in case of safety issues. By transplanting these engineered striatal progenitor cells (STRpcs) into the striatum of R6/2 mice (a mouse model of HD), the study evaluated the improvement effect of this treatment method on HD symptoms and its safety. ### Main research contents: 1. **Engineered hPSCs**: The researchers first started from the existing hESCs (H9 line) and used CRISPR/Cas9 technology to edit genes, enabling these cells to over - express BDNF or NT3 and contain two inducible safety switches to prevent possible safety risks such as tumor formation. 2. **Differentiation into neural precursor cells**: These engineered hPSCs were then differentiated into neural precursor cells (hNPCs) and further processed to differentiate into striatal progenitor cells (STRpcs). 3. **Transplantation experiment**: These STRpcs were transplanted into the striatum of R6/2 mice to evaluate their improvement effects on HD - related symptoms, including tests on motor coordination, cognitive function, and social behavior. 4. **Safety mechanism verification**: By activating the safety switch, it was verified that the transplanted cells can be safely eliminated when necessary, thus ensuring the safety of the treatment. ### Research results: - Transplanting STRpcs over - expressing BDNF significantly improved the motor coordination ability, cognitive function, and social behavior of R6/2 mice. - After activating the safety switch, the transplanted cells could be effectively eliminated, indicating that this treatment platform has high safety. ### Conclusion: This study shows that by engineering hPSCs and combining safety mechanisms, the symptoms of HD can be effectively alleviated and has high safety. This finding provides new ideas and methods for the treatment of HD and other neurodegenerative diseases.